BTIG downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Neutral.The firm noted: We believe Valeant needs to sever its relationship ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Downgrades

Valeant Pharmaceuticals (VRX) Bull-Bear Debate RagesOctober 30, 2015 12:57 PM Bill Ackman said Valeant Pharma (VRX) worth $180-$240 Near-Term, $262-$350 Long-TermOctober 30, 2015 10:14 AM Valeant Pharma (VRX) on Watch as Ahead of Pershing Square Conference CallOctober 30, 2015 8:53 AM Valeant Pharma (VRX) to Sever Ties with PhilidorOctober 30, 2015 5:59 AM